becton dickinson compani
may pm et
summari compani provid wide rang medic devic diagnost product use
hospit doctor offic research lab set
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
expect fy sep sale inclus
 bard bcr acquisit late decemb
rise follow
declin fy due divestitur
respiratori solut unit report
three busi segment medic life
scienc intervent see oper
margin fy fy
devic compani focus vascular
urolog oncolog market
cash share bcr
share total enterpris valu
china one fastest grow market
combin compani lead global
presenc sale oversea includ
china
may earn call commun
organiz design integr
plan acquir bard busi fulli
place expect see gross margin
expand substanti
even
integr cost see oper
ebit margin improv fy
fy fy
fy ep estim
view bcr deal posit see bcr
acceler sale growth expand
margin deal immedi
accret earn expect
gener high-single-digit accret fy
sep estim million
cost synergi fy believ
compani execut acquisit
increas leverag ebitda
end decemb plan de-lev
within three year
encourag strong global demand
safeti diabet care diseas
test product see
sustain revenu gener long
term forward earn think
attract valu
risk opinion target price includ
slower-than-expect realiz synergi
recent acquisit macroeconom
pressur key end market given
target price
ep estim
multipl slightli peer toward
high-end three-year rang
posit view chang
market competit new product
introduct competitor potenti
significantli affect market dynam chang
domest foreign health care industri practic
regul may result increas price pressur
lower reimburs product still
product line favor demand price
characterist medic equip
industri gener
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
becton dickinson compani
execut vice-president global
becton dickinson compani trace root concern start maxwel becton fairleigh
dickinson one first compani sell -made glass syring also pioneer
product hypoderm needl compani manufactur sell medic suppli
devic lab equip diagnost product use health care institut life scienc research
clinic laboratori industri gener public
major product core medic system divis includ hypoderm syring needl inject
insulin syring pen needl diabet care infus therapi devic prefil drug deliveri
system surgic blade scalpel segment also market specialti blade cannula
ophthalm surgeri procedur anesthesia needl critic care system elast support product
diagnost segment provid rang product design safe collect transport
diagnost specimen instrument analysi across wide rang infecti diseas test
includ health care-associ infect hai princip product servic includ integr
system specimen collect extens line safety-engin blood collect product
system plate media autom blood cultur system molecular test system sexual
transmit diseas hai microorgan identif drug suscept system liquid-bas
cytolog system cervic cancer screen rapid diagnost assay segment also includ
consult servic custom autom bar-cod system patient identif
bioscienc unit provid research tool reagent clinician medic research studi
gene protein cell order better understand diseas improv diagnosi diseas
manag facilit discoveri develop novel therapeut product includ
instrument system cell sort analysi monoclon antibodi reagent kit diagnost
research use tool aid drug discoveri vaccin develop molecular biolog product fluid
handl cell growth screen product
march acquir carefus cfn billion share consist cash
share cfn share cfn lead provid medic devic diagnost
product hospit physician
august acquir sirigen group ltd develop polym dye use flow cytometri
august acquir carmel pharma ab swedish compani manufactur phaseal
lead closed-system drug transfer devic safe handl hazard drug
packag vial acquisit expand scope health care worker safeti emphasi
develop manufactur person flow cytomet research
decemb compani acquir remain stake tripath imag inc
alreadi per share cash million tripath sell product use diagnos cancer
emerg molecular oncolog busi also took in-process charg
million associ three project molecular pap test use proprietari molecular biomark
reagent intend allow primari screen cervic cancer breast stage use
proprietari molecular biomark reagent intend predict risk diseas recurr
aid treatment select patient earli stage breast cancer ovarian cancer detect
intend allow serum-bas screen monitor assay ovarian cancer base upon
detect multipl biomark use proprietari panel biomark assay algorithm
april compani open second manufactur facil suzhou china new bd
diagnost facil produc rapid diagnost product flu viral infect initi focu
influenza respiratori syncyti viru time becton expect expand rang diseas
product diagnos includ addit bacteri parasit viral diseas product made
plant sold global market includ asia europ latin america north america
august complet sale ophthalm system unit surgic blade critic
care extend dwell cathet product platform asset gener approxim million
annual revenu octob compani sold discoveri labwar unit exclud advanc
bioprocess platform corn inc million labwar unit annual sale
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
base cfra proprietari quantit model
stock rank overvalu
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fundament outlook health care
equip sub-industri next month
posit continu view mani product
categori histor recession-resist
expect continu grow growth
procedur rate area view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped steadili improv
see continu recoveri
medic devic tax requir
healthcar reform law went effect
januari temporarili suspend
januari
congress pass stopgap measur includ
suspend medic devic tax anoth
two year tax
slate becom effect januari
decemb congress pass tax cut
job act includ repeal
individu mandat compon
afford act requir
peopl health insur pay fine
effect januari believ repeal
individu mandat result fewer
insur peopl neg impact
equip sub-industri fewer insur
patient would like lead fewer procedur
anticip hospit
largest buyer medic equip would also
advers impact could
pressur sub-industri
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
pressur lower demand certain product
categori affect sale growth also think
 hospit becom cautiou
regard capit budget amid shift
base index
five-year market price perform may
procedur inpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
 composit index year
date april health
declin composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
sep ep estim sale divestitur respiratori
solut unit fell pro forma basi sale rose bd medic sale
pro forma basi rose bd life scienc rose pend
acquisit cr bard track close fourth quarter calendar year
see deal acceler sale margin /jeffrey loo cfa
et cfra rais opinion share becton dickinson buy
hold agre buy cr bard bcr
lead devic firm vascular urolog oncolog share
consist cash share bcr share
combin compani lead global presenc medic
manag infect prevent vascular surgic specialti
sale includ china view deal posit
see bcr acceler sale expand margin rais
target slightli peer ep estim
/jeffrey loo cfa
dickinson compani keep target
in-lin peer revis fy sep ep estim
dec-q ep vs estim sale
includ divestitur respiratori solut unit fell
medic unit life scienc oper margin rose
benefit portfolio restructur updat fy
sale guidanc reflect greater advers fx impact sale respiratori
solut see sale declin ep
analyst research note compani news
compani rais target
next-twelve-month ep estim multipl near
high-end bdx three-year rang slightli
peer averag mar-q ep vs higher
estim rais sep ep estim
ep mar-q sale increas
billion driven dec acquisit cr bard organ
basi revenu grew compris growth bd medic revenu
growth bd life scienc growth bd intervent
paid million debt mar-q brought gross leverag
debt-ebitda dec commun
organiz design integr plan acquir bard busi
fulli in-plac look forward well execut plan /kevin
et cfra add becton dickinson high qualiti capit
appreci portfolio lead supplier
medic suppli equip devic hospit physician
implement multi-year product portfolio restructur move
faster grow higher margin busi primarili acquisit
divest slower grow lower margin product acquir
carefus decemb acquir cr bard
oper margin expand
see expans replac
compani rais target price
line peer fy sep ep estim
inclus bard set fy dec-q ep vs
ahead estim sale rose bd medic
bd life scienc robust diagnost system sale aid
earlier flu season expect robust sale emerg market
china continu fy look integr
bard lift gross margin bp oper margin bp
set fy sept ep estim
account pend acquisit cr bard bcr
pend divestitur soft tissu core needl biopsi product line
bcr aspira product line expect bcr
acquisit relat divestitur complet shortli reiter
forecast bcr deal acceler sale margin
updat model upon deal complet keep target price
in-lin peer fy ep estim /jeffrey
compani rais target in-lin
peer fy sept ep estim sept-
ep estim sale account
divestitur respiratori solut fell pro forma basi sale rose
bd medic pro forma sale rose bd life scienc rose
stand-alon basi see fy sept sale growth
ep pend acquisit cr bard bcr
track close fourth quarter calendar /jeffrey loo cfa
compani rais target price
in-lin peer forward ep estim jun-q
ep vs in-lin ahead estim rais fy
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
becton dickinson compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
